Navigation Links
FDA Warns About Antipsychotic Drugs and Elderly

The Food and Drug Administration (FDA) today issued a public health advisory to alert health care providers, patients, and patient caregivers to new safety information concerning an unapproved (i.e., "off-label") use of certain drugs called "atypical antipsychotic drugs." These drugs are approved for the treatment of schizophrenia and mania, but clinical studies of these drugs to treat behavioral disorders in elderly patients with dementia have shown a higher death rate associated with their use compared to patients receiving a placebo (sugar pill).

Today's advisory applies to such antipsychotic drugs as Abilify (aripiprazole), Zyprexa (olanzapine), Seroquel (quetiapine), Risperdal (risperidone), Clozaril (clozapine) and Geodon (ziprasidone). Symbyax, which is approved for treatment of depressive episodes associated with bipolar disorder is also included in the agency's advisory.

FDA is requesting that the manufacturers of all of these kinds of drugs add a boxed warning to their drug labeling describing this risk and noting that these drugs are not approved for the treatment of behavioral symptoms in elderly patients with dementia. Patients receiving these drugs for treatment of behavioral disorders associated with dementia should have their treatment reviewed by their health care providers.
In analyses of seventeen placebo-controlled studies of four drugs in this class, the rate of death for those elderly patients with dementia was about 1.6 to 1.7 times that of placebo. Although the causes of death were varied, most seemed to be either heart-related (such as heart failure or sudden death) or from infections (pneumonia).

The atypical antipsychotics fall into three drug classes based on their chemical structure. Because the increase in mortality was seen with atypical antipsychotic medications in all three chemical classes, the agency has concluded that the effect is probably related to the common pharmacologic effects of all atypical an tipsychotic medications, including those that have not been studied in the dementia population.

The agency is considering adding a warning to the labeling of older antipsychotic medications because limited data also suggest a similar increase in mortality for these drugs. The review of the data on these older drugs, however, is still on-going.


'"/>

Source:U.S. FDA


Related biology news :

1. FDA Warns Consumers Not to Use Home-Use Diagnostic Kits Marketed by Globus Media
2. WHO Warns Of Increased Risk Of Vector-borne Diseases In Tsunami-affected Areas
3. HIV Patients May Be at Risk of Heart Problems When Taking Protease Inhibitor Drugs
4. New Drugs For Bad Bugs: UF Approach Could Bolster Antibiotic Arsenal
5. FDA Announces Series of Changes to the Class of Marketed Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
6. Computational Tool Predicts How Drugs Work In Cells, Advancing Efforts To Design Better Medicines
7. Discovery of New Dopamine Action May Yield Alternative Psychiatric Drugs
8. Drugs from the deep blue
9. Engineered Stem Cells Show Promise For Sneaking Drugs Into The Brain
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
(Date:3/23/2016)... 23, 2016 ... Gesichts- und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler ... mit SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie ... die Möglichkeit angeboten, im Rahmen mobiler Apps ...
Breaking Biology News(10 mins):
(Date:4/29/2016)... ... , ... Intelligent Implant Systems announced today that the two-level components for the ... United States. These components expand the capabilities of the system and allow Revolution™ ... October of 2015, the company has seen significant sales growth in 1Q 2016, and ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... will deliver a talk on its first-in-class technologies for tissue stem cell counting ... on RNAiMicroRNA Biology to Reprogramming & CRISPR-based Genome Engineering in Burlington, Massachusetts. ...
(Date:4/27/2016)... ... ... The Pittcon Organizing Committee is pleased to announce that Charles “Chuck” Gardner was named ... 1987. Since then, he has served in a number of key leadership positions including ... program and exposition committees. In his professional career, Dr. Gardner is the director of ...
(Date:4/27/2016)... ... 27, 2016 , ... NDA Partners Chairman Carl Peck, ... Expert Consultant. Mr. Clark was formerly a Vice President with US Pharmacopeia, ... molecule monographs based on analytical methods. NDA Partners Expert Consultants are top ...
Breaking Biology Technology: